| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
PBP Stock Overview
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast moving consumer products in Australia and internationally.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.36 |
| 52 Week High | AU$2.45 |
| 52 Week Low | AU$1.92 |
| Beta | 0.51 |
| 1 Month Change | 6.31% |
| 3 Month Change | 9.77% |
| 1 Year Change | -1.67% |
| 3 Year Change | 57.33% |
| 5 Year Change | 337.04% |
| Change since IPO | 104.33% |
Recent News & Updates
Shareholder Returns
| PBP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -0.8% | -2.5% | -1.7% |
| 1Y | -1.7% | -12.9% | 7.7% |
Return vs Industry: PBP exceeded the Australian Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: PBP underperformed the Australian Market which returned 9.7% over the past year.
Price Volatility
| PBP volatility | |
|---|---|
| PBP Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.3% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: PBP is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PBP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Wes Stringer | https://www.probiotec.com.au |
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, ointments, and suspensions; powders and powder blending; and sprays, as well as manufactures and packages finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Fundamentals Summary
| PBP fundamental statistics | |
|---|---|
| Market Cap | AU$191.92m |
| Earnings (TTM) | AU$5.07m |
| Revenue (TTM) | AU$120.51m |
37.9x
P/E Ratio1.6x
P/S RatioIs PBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBP income statement (TTM) | |
|---|---|
| Revenue | AU$120.51m |
| Cost of Revenue | AU$81.81m |
| Gross Profit | AU$38.70m |
| Expenses | AU$33.63m |
| Earnings | AU$5.07m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.062 |
| Gross Margin | 32.11% |
| Net Profit Margin | 4.21% |
| Debt/Equity Ratio | 72.8% |
How did PBP perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield76%
Payout RatioValuation
Is Probiotec undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PBP (A$2.36) is trading below our estimate of fair value (A$30.24)
Significantly Below Fair Value: PBP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PBP is poor value based on its PE Ratio (37.9x) compared to the Global Pharmaceuticals industry average (24.4x).
PE vs Market: PBP is poor value based on its PE Ratio (37.9x) compared to the Australian market (19.3x).
Price to Earnings Growth Ratio
PEG Ratio: PBP is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: PBP is good value based on its PB Ratio (2.8x) compared to the AU Pharmaceuticals industry average (3x).
Future Growth
How is Probiotec forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
27.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBP's forecast earnings growth (27.3% per year) is above the savings rate (1.9%).
Earnings vs Market: PBP's earnings (27.3% per year) are forecast to grow faster than the Australian market (11.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PBP's revenue (12.7% per year) is forecast to grow faster than the Australian market (4.9% per year).
High Growth Revenue: PBP's revenue (12.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBP's Return on Equity is forecast to be low in 3 years time (18.2%).
Past Performance
How has Probiotec performed over the past 5 years?
19.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PBP has high quality earnings.
Growing Profit Margin: PBP's current net profit margins (4.2%) are lower than last year (6%).
Past Earnings Growth Analysis
Earnings Trend: PBP's earnings have grown by 19.7% per year over the past 5 years.
Accelerating Growth: PBP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PBP had negative earnings growth (-21.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.3%).
Return on Equity
High ROE: PBP's Return on Equity (7.4%) is considered low.
Financial Health
How is Probiotec's financial position?
Financial Position Analysis
Short Term Liabilities: PBP's short term assets (A$67.8M) exceed its short term liabilities (A$44.4M).
Long Term Liabilities: PBP's short term assets (A$67.8M) do not cover its long term liabilities (A$117.8M).
Debt to Equity History and Analysis
Debt Level: PBP's net debt to equity ratio (31.4%) is considered satisfactory.
Reducing Debt: PBP's debt to equity ratio has increased from 13.2% to 72.8% over the past 5 years.
Debt Coverage: PBP's debt is well covered by operating cash flow (48.8%).
Interest Coverage: PBP's interest payments on its debt are well covered by EBIT (3.3x coverage).
Balance Sheet
Dividend
What is Probiotec current dividend yield, its reliability and sustainability?
2.12%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PBP's dividend (2.12%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.18%).
High Dividend: PBP's dividend (2.12%) is low compared to the top 25% of dividend payers in the Australian market (5.36%).
Stability and Growth of Payments
Stable Dividend: PBP has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: PBP's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (75.6%), PBP's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PBP's dividends in 3 years are forecast to be well covered by earnings (44.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average board tenure
CEO
Wes Stringer
6.5yrs
Tenure
AU$872,983
Compensation
Mr. Wesley Stringer, also known as Wes, B.Comm (Accounting, Finance), LLB (Hons), CPA, has been the Chief Executive Officer of Probiotec Limited since July 1, 2015 and serves as its managing Director. Mr....
CEO Compensation Analysis
Compensation vs Market: Wes's total compensation ($USD627.05K) is above average for companies of similar size in the Australian market ($USD290.45K).
Compensation vs Earnings: Wes's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Board Members
Experienced Board: PBP's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
Top Shareholders
Company Information
Probiotec Limited's employee growth, exchange listings and data sources
Key Information
- Name: Probiotec Limited
- Ticker: PBP
- Exchange: ASX
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$191.923m
- Shares outstanding: 81.32m
- Website: https://www.probiotec.com.au
Location
- Probiotec Limited
- 83 Cherry Lane
- Laverton North
- Victoria
- 3026
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/19 15:39 |
| End of Day Share Price | 2022/01/19 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.